Cohorts of wild‐type mice were provided an adenine‐containing diet to induce CKD as we previously described (Clinkenbeard et al., 2019), and were then treated with either recombinant human EPO (“EPO” cohort) or the HIF‐PHD inhibitor FG‐4592 (“FG” cohort). The gene discussed is EPO; the disease is chronic kidney disease.